Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for gastrointestinal cancers, including gastrointestinal stromal tumors (GIST) and familial adenomatous polyposis (FAP), as well as tolimidone for type 1 diabetes. Its pipeline includes eRapa, an oral rapamycin formulation being developed for FAP and non-muscle-invasive bladder cancer; MTX240, a molecular glue licensed for development initially in GIST; and tolimidone. MTX110, a candidate for rare brain cancers, is no longer a key program. Biodexa is headquartered in Cardiff, Wales. Biodexa licenses drug candidates from other companies and develops them through clinical proof of concept. It uses contract manufacturers for clinical trial materials and generally intends to license products to partners for later development and marketing. Under those arrangements, it may receive development-cost reimbursement, milestone payments and royalties.
No SEC Form 4 filings for $BDRX in the last 30 days.
See all $BDRX insider activity →Biodexa Pharmaceuticals (BDRX) enrolled 112 of 168 participants in its Phase 3 Serenta FAP trial. A futility analysis may occur in early 2027, with database lock around year-end 2027. MTX240 Phase 1a recruitment is expected to begin in South Korea in mid-2027, according to the company.
Biodexa Pharmaceuticals (BDRX) has enrolled 100 patients in its Phase 3 trial for eRapa, a treatment for Familial Adenomatous Polyposis (FAP). The trial, called Serenta, is recruiting at 29 sites in the US and Europe, with two more in Canada to start soon. The company expects a futility analysis early next year and database lock by the end of next year, earlier than initially anticipated.
Biodexa Pharmaceuticals (BDRX) CEO Stephen Stamp discussed the company's lead drug candidate, eRapa, for treating Familial Adenomatous Polyposis (FAP). The Phase 3 trial, Serenta, is over 50% enrolled with interim data expected in Q1 2027. eRapa aims to reduce surgical interventions, and the company has received $20M in grant funding. Biodexa claims a development lead over competitors, with a focus on safety and convenience.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning BDRX (Biodexa Pharmaceuticals Plc). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent BDRX coverage spans financial news, technology and earnings.
Enrollment progress is a neutral update; no efficacy data yet, so price impact is limited.
The enrollment milestone may lift sentiment and drive short-term buying as investors anticipate positive trial data.
Positive trial progress and significant grant funding may reduce risk perception and support upside.
Recovery suggests short covering and possible positive news.
Recruitment progress reduces execution risk and may boost investor confidence ahead of upcoming futility analysis.
AlphAI scores every news story that mentions BDRX with an AI model for sentiment and relevance, and aggregates insider trades from Biodexa Pharmaceuticals Plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Biodexa Pharmaceuticals (BDRX) enrolled 112 of 168 participants in its Phase 3 Serenta FAP trial. A futility analysis may occur in early 2027, with database lock around year-end 2027. MTX240 Phase 1a recruitment is expected to begin in South Korea in mid-2027, according to the company.
Biodexa Pharmaceuticals (BDRX) has enrolled 100 patients in its Phase 3 trial for eRapa, a treatment for Familial Adenomatous Polyposis (FAP). The trial, called Serenta, is recruiting at 29 sites in the US and Europe, with two more in Canada to start soon. The company expects a futility analysis early next year and database lock by the end of next year, earlier than initially anticipated.
Biodexa Pharmaceuticals (BDRX) CEO Stephen Stamp discussed the company's lead drug candidate, eRapa, for treating Familial Adenomatous Polyposis (FAP). The Phase 3 trial, Serenta, is over 50% enrolled with interim data expected in Q1 2027. eRapa aims to reduce surgical interventions, and the company has received $20M in grant funding. Biodexa claims a development lead over competitors, with a focus on safety and convenience.
RH (NYSE:RH) shares rose 8.2% in pre-market trading after reporting Q2 earnings of $2.70 per share, beating estimates by 51.69%. Revenue was $922.15M, up from last year but below expectations. Other movers included Oracle (NYSE:ORCL), Alliance Entertainment (NASDAQ:AENT), and ACV Auctions (NYSE:ACVA).
Biodexa Pharmaceuticals (BDRX) has enrolled 87 of 168 planned patients in its Phase 3 Serenta trial for eRapa in Familial Adenomatous Polyposis (FAP), with sites in the U.S. and Europe. The trial aims to evaluate eRapa, a rapamycin-based treatment, with a $20M grant supporting the program. BDRX stock is up 6.62% to $23.82.
Biodexa Pharmaceuticals PLC has issued a letter to shareholders detailing proposals to reorganize the company’s share capital at the upcoming Annual General Meeting. These proposals aim to rationalize the share capital by reducing the number of ordinary shares without affecting shareholders' rights, percentage ownership, or the number of American Depositary Shares (ADSs) outstanding. The changes involve a reverse split, subdivision, redesignation of shares, and an adjustment to the ordinary share/ADS ratio, all recommended by the Board.
Biodexa Pharmaceuticals plans a significant capital reorganization at its June 17, 2026 AGM, including a 10,000:1 reverse stock split of its ordinary shares and a change in the ordinary share/ADS ratio from 500,000:1 to 50:1. This move is intended to rationalize the company's share capital and administration without affecting the number of American Depositary Shares (ADSs) held, shareholders' percentage ownership, or their rights. The proposal also involves creating new E deferred shares with negligible rights, with the changes being inter-conditional and effective on June 18, 2026, if approved.
Biodexa Pharmaceuticals PLC-ADR ( NASDAQ:BDRX ) saw its stock fall 3.67% to $10.50 during after-hours trading on Thursday. Check out the current price of BDRX stock here.
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
